You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel Screen Approach to Inactivate Whole Viral Vaccines by Supralethal Irradiation

    SBC: AGAVE BIOSYSTEMS INC.            Topic: DTRA14B002

    Future vaccine development should focus on rapid upscale production, long-term and broad protection, and sufficient global distribution to prevent and reduce the impact of many infectious diseases and potential epidemics. Agave BioSystems proposes to develop a novel whole-microorganism vaccine inactivation strategy involving high-throughput screen of extensive radio-protectant matrices and radiati ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
  2. A Novel, Microscale, Distributable Sensor Technology for Ionizing Radiation

    SBC: CFD Research Corporation            Topic: DTRA14B004

    Terrorist use of radioactive nuclear materials via nuclear and/or radiological dispersion devices (dirty bombs) is a serious threat. Therefore, it is critical to detect the proliferation of nuclear material. Critical challenges facing this objective include: (a) high sensitivity detection of signature emissions (e.g., gamma rays) from common radioactive isotopes behind shielding, and (b) cost-effe ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
  3. Portable System with Li Foil MWPC Neutron Detectors

    SBC: Radiation Detection Technologies, Inc.            Topic: DTRA14B005

    At the completion of the research and development effort a Li foil multi-wire proportional counter (MWPC) neutron detector with more than 625 cm^2 of active area will be included in a portable radiation detection system. The system is expected to have an intrinsic thermal neutron detection efficiency of 55% or greater and gamma-ray rejection ratio (GRR) of 1.0x10^-8 or better. A gamma-ray spectrom ...

    STTR Phase I 2015 Department of DefenseDefense Threat Reduction Agency
  4. Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicine

    SBC: 490 BIOTECH INC            Topic: 200

    DESCRIPTION provided by applicant This Small Business Technology Transfer STTR Phase I project proposes to develop autonomously bioluminescent human stem cells for continuous reagent free and real time bioimaging to address the National Institutes of Healthandapos s request for new techniques for non invasive long term tracking of stem cell survivability engraftment and migration followi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. A Novel Approach to Purifying iPSC Derived Cell Cultures

    SBC: HocusLocus Inc.            Topic: 200

    DESCRIPTION provided by applicant We are pioneering an RNA based switch technology called structurally interacting RNAs sxRNA which utilizes post transcriptional gene regulation as a reporter for miRNA detection Normally RNA binding proteins RBP associate with a andapos stem loop structure to facilitate translation of an upstream coding region by as much as an order of magnitude It is ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    DESCRIPTION provided by applicant As part of the FDA approval process for novel therapeutic drugs safety screening demonstrating that the new drug does not have deleterious effects on the human cardiac action potential is required Healthy human heart cells are not available for such preclinical drug testing There is currently no consensus on the best experimental approach to provide the most ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Evaluation of TRB-N0224, a Proprietary Chemically Modified Curcumin, for the Treatment of Periodontal Disease in a LPS-Induced Rat Model

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIDCR

    DESCRIPTION provided by applicant Traverse Biosciences Inc is a pre clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host modulation of pathologically unrestrained matrix metalloproteinases MMPs and pro inflammatory cytokines The companyandapos s lead drug candidate TRB N is a propri ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a high-throughput assay for measuring m6A demethylase activity

    SBC: Base5 Biosciences Inc            Topic: NIDA

    DESCRIPTION provided by applicant N methyladenosine m A was recently discovered to be a widespread base modification present in thousands of mammalian mRNAs In addition to its prevalence throughout the transcriptome researchers have also revealed that m A is a reversible modification suggesting that dynamic regulation of mRNA methylation is a novel and widespread RNA regulatory mechanism ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Technology-Guided Opioid Cessation for Post-Operative Pain

    SBC: MedicaSafe Inc            Topic: R41

    DESCRIPTION provided by applicant This STTR application proposes development of MedicaSafe Inc andapos s Multimodal Analgesic Protection System MAPSafe Built around MedicaSafeandapos s proprietary Medication Therapy Optimization MTO technology MAPSafe will be designed to mitigate the myriad risks associated with prescription opioid use post operatively and throughout recovery after surge ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Novel Membrane Protein Solubilization/Stabilization Screen

    SBC: SOLUBLE THERAPEUTICS, INC            Topic: 100

    DESCRIPTION provided by applicant The increasing output of new integral membrane protein IMP structures is partially due to the availability of an increasing number of chemical variables such as detergents detergent like molecules lipids and solubilizing stabilizing additives It is clear that specific combinations and concentrations of these different variables are often necessary to impr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government